Geoffrey Hulme Net Worth

The estimated Net Worth of Geoffrey Hulme is at least 136 千$ dollars as of 15 February 2019. Geoffrey Hulme owns over 7,000 units of Innoviva Inc stock worth over 135,800$ and over the last 6 years Geoffrey sold INVA stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Geoffrey Hulme INVA stock SEC Form 4 insiders trading

Geoffrey has made over 1 trades of the Innoviva Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Geoffrey bought 7,000 units of INVA stock worth 103,600$ on 15 February 2019.

The largest trade Geoffrey's ever made was buying 7,000 units of Innoviva Inc stock on 15 February 2019 worth over 103,600$. On average, Geoffrey trades about 1,400 units every 0 days since 2019. As of 15 February 2019 Geoffrey still owns at least 7,000 units of Innoviva Inc stock.

You can see the complete history of Geoffrey Hulme stock trades at the bottom of the page.

Insiders trading at Innoviva Inc

Over the last 9 years, insiders at Innoviva Inc have traded over 394,127,811$ worth of Innoviva Inc stock and bought 682,000 units worth 8,768,520$ . The most active insiders traders include Plc Gsk、Alexander J Sarissa Capital...、Patrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of 18,199,955$. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth 153,806$.

What does Innoviva Inc do?

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.

Complete history of Geoffrey Hulme stock trades at Innoviva Inc

Innoviva Inc executives and stock owners

Innoviva Inc executives and other stock owners filed with the SEC include:

• Marianne Zhen,
  Chief Accounting Officer
• Marianne Zhen CPA,
  Chief Accounting Officer
• Pavel Raifeld C.F.A.,
  Chief Exec. Officer
• George Bickerstaff,
  Independent Director
• Jules Haimovitz,
  Independent Director
• Odysseas Kostas,
  Independent Chairman of the Board
• Sarah Schlesinger,
  Independent Director
• Mark DiPaolo,
  Independent Director
• Pavel Raifeld,
  Chief Executive Officer
• Paul Pepe,
  Director
• Michael W Aguiar,
  President & Chief Exec Officer
• Barbara Gayle Duncan,
  Director
• William H Waltrip,
  Director
• Theodore L Jr Witek,
  Sr. VP & Chief Scientific Off.
• Cathy Friedman,
  Director
• James L Tyree,
  Director
• Michael E. Faerm,
  Sr VP & Chief Business Officer
• George B Abercrombie,
  Sr. VP & Chief Comm. Officer
• Patrick G Lepore,
  Director
• Eric D Esparbes,
  SVP and CFO
• Alexander J Sarissa Capital...,
  
• Matthew Ronsheim,
  See Remarks
• Geoffrey Hulme,
  Interim Principal Exec Officer
• Deborah Birx,
  Director
• Plc Gsk,
  10% owner
• Derek A Small,
  Director
• Sapna Srivastava,
  Director
• Margaret Koziel,
  Chief Medical Officer
• Stephen Basso,
  Chief Financial Officer